Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Amgen (AMGN) Stock Pops 4% as Sjögren’s Drug Could Be First of Its Kind

AI-generated analysis

📈 AMGN stock jumped roughly 4% in premarket trading to hit $406.02 after reporting positive Phase 3 trial results for its Sjögren's disease drug, dazodalibep.

✅ The OASIZ 301 study met its primary endpoint with patients showing statistically meaningful improvement in systemic disease activity at Week 48.

🔬 Dazodalibep demonstrated early efficacy improvements as soon as Week 4 that held through the end of the 48-week trial period.

💊 The drug is a CD40L antagonist fusion protein targeting T cells, B cells, and other immune cells to disrupt disease-driving interactions.

🛡️ Safety data showed low discontinuation rates due to side effects, which were mild to moderate and similar across treatment and placebo groups.

🚀 If approved, dazodalibep would be the first FDA-approved treatment for Sjögren's, a systemic autoimmune disease currently lacking approved medicines.

📅 Amgen plans to present full data from OASIZ 301 at an upcoming medical conference to provide further clarity on the drug's profile.

🔭 A second Phase 3 study, OASIZ 303, is underway and expected to wrap up in Q4 2026 for patients with moderate-to-severe symptomatic Sjögren's disease.

Bullish Signals
  • Amgen stock jumped roughly 4% in premarket trading to hit $406.02 following positive topline results from the Phase 3 trial of its experimental Sjögren's disease drug, dazodalibep.
  • The OASIZ 301 trial met its primary endpoint with patients showing statistically meaningful improvement in systemic disease activity at Week 48.
  • Dazodalibep demonstrated therapeutic benefits as early as Week 4 that persisted through the full 48-week period of the study.
  • The drug represents a potential first-in-class therapy for Sjögren's, a condition currently lacking any FDA-approved medicines.
Full Analysis
Amgen (AMGN) shares surged approximately 4% in premarket trading to reach $406.02 following the announcement of positive topline results from its Phase 3 clinical trial, OASIZ 301, for dazodalibep, an experimental treatment for Sjögren's disease. The study met its primary endpoint, demonstrating statistically meaningful improvements in systemic disease activity at Week 48 as measured by the ESSDAI index among 621 patients with moderate-to-severe conditions. The trial data indicated that therapeutic benefits were observable as early as Week 4 and persisted through the full 48-week duration. Dazodalibep functions as a CD40L antagonist fusion protein designed to disrupt immune cell interactions driving the autoimmune disease. Notably, there are currently no FDA-approved medicines for Sjögren's, positioning dazodalibep as a potential first-in-class therapy if regulatory approval is granted. Safety profiles observed in the trial were manageable, with common side effects including nasopharyngitis and hypertension occurring at mild to moderate levels. Discontinuation rates due to adverse events were low and comparable between treatment and placebo groups. Amgen plans to present full data at an upcoming medical conference, while a second Phase 3 study is expected to conclude in Q4 2026.